Inhibikase Therapeutics, Inc.
IKT
$1.67
$0.000.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -8.72M | -10.06M | 3.36M | -102.90K | -2.30M |
| Gross Profit | 8.72M | 10.06M | -3.36M | 102.90K | 2.30M |
| SG&A Expenses | 25.68M | 23.56M | 22.52M | 18.54M | 14.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -358.40K | -358.40K | -358.40K | -358.40K | -- |
| Total Operating Expenses | 48.04M | 45.59M | 52.79M | 45.35M | 39.57M |
| Operating Income | -48.04M | -45.59M | -52.79M | -45.35M | -39.57M |
| Income Before Tax | -50.96M | -48.26M | -47.66M | -41.50M | -36.55M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -50.96 | -48.26 | -47.66 | -41.50 | -36.55 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.96M | -48.26M | -47.66M | -41.50M | -36.55M |
| EBIT | -48.04M | -45.59M | -52.79M | -45.35M | -39.57M |
| EBITDA | -47.98M | -45.53M | -52.72M | -45.30M | -39.54M |
| EPS Basic | -0.44 | -0.50 | -0.56 | -1.08 | -1.63 |
| Normalized Basic EPS | -0.24 | -0.28 | -0.36 | -0.68 | -1.03 |
| EPS Diluted | -0.44 | -0.50 | -0.56 | -1.08 | -1.63 |
| Normalized Diluted EPS | -0.24 | -0.28 | -0.36 | -0.68 | -1.03 |
| Average Basic Shares Outstanding | 476.00M | 393.24M | 341.67M | 260.50M | 178.03M |
| Average Diluted Shares Outstanding | 476.00M | 393.24M | 341.67M | 260.50M | 178.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |